Product Description
Dapsone , a sulfone, belongs to the family of medicines called anti-infectives. Dapsone is used to treat leprosy (Hansen's disease) and to help control dermatitis herpetiformis, a skin problem. (Sourced from: https://www.mayoclinic.org/drugs-supplements/dapsone-oral-route/proper-use/drg-20063327?p=1)
Mechanisms of Action: DHFR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Bangladesh | Brazil | Canada | Chile | Colombia | Ecuador | Egypt | France | Germany | Greece | Hong Kong | India | Ireland | Korea | Lithuania | Malaysia | Malta | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Portugal | Romania | Russia | Slovakia | Slovenia | South Africa | Spain | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Vietnam
Approved Indications: Acne Vulgaris
Known Adverse Events: Pruritus
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|